Family Medicine & Primary Care Review
eISSN: 2449-8580
ISSN: 1734-3402
Family Medicine & Primary Care Review
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search

Open access

without publication fees
1/2025
vol. 27
 
Share:
Send email
Share:
Original paper

The impact of biological treatment on the clinical response and functioning of patients with rheumatoid arthritis

Iwona Malinowska-Lipień
1
,
Agnieszka Cepielik
2
,
Anna Kliś-Kalinowska
1
,
Dorota Poręba
3
,
Łukasz Lompart
1
,
Urszula Kalemba
4
,
Jakub Lickiewicz
1

  1. Institute of Nursing and Midwifery, Faculty of Health Sciences, Jagiellonian University – Medical College, Cracow, Poland
  2. Institute of Nursing and Midwifery, Faculty of Health Sciences, Jagiellonian University – Medical College, Cracow, Poland (absolvent)
  3. Podhale State School of Higher Vocational Education in Nowy Targ, Nowy Targ, Poland
  4. Long-Term Care Facility, Specialist Hospital Ludwik Rydygier in Cracow, Cracow, Poland
Family Medicine & Primary Care Review 2025; 27(1): 57–62
DOI: https://doi.org/10.5114/fmpcr.2025.146971
Online publish date: 2025/03/26
Article file
- 09 FM&PCR 1 25 - O - Malinowska-Lipień -1629 - The impact.pdf  [0.31 MB]
Get citation
 
PlumX metrics:
 
1. Kawalec P, Śladowska K, Malinowska-Lipień I, et al. European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib. Ther Clin Risk Manag 2018; 14: 15–29.
2. Chauhan K, Jandu JS, Brent LH. Rheumatoid Arthritis. In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2023 [cited 01.11.2023]. Available from URL: https://www.ncbi.nlm.nih.gov/books/NBK441999/.
3. McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet 2017; 389(10086): 2328–2337, doi: 10.1016/s0140-6736(17)31472-1.
4. Finckh A, Gilbert B, Hodkinson B, et al. Global epidemiology of rheumatoid arthritis. Nat Rev Rheumatol 2022; 18(10): 591–602.
5. Almutairi KB, Nossent JC, Preen DB, et al. The Prevalence of Rheumatoid Arthritis: A Systematic Review of Population-based Studies. J Rheumatol 2021; 48(5): 669–676.
6. Radu AF, Bungau SG, Negru PA, et al. In-depth bibliometric analysis and current scientific mapping research in the context of rheumatoid arthritis pharmacotherapy. Biomed Pharmacother 2022; 154: 113614.
7. Sanchez-Florez CJ, Seija-Butnaru D, Valero GE, et al. Pain Management Strategies in Rheumatoid Arthritis: a Narrative Review. J Pain Palliat Care Pharmacother 2021; 35(4): 291–299.
8. Kawalec P, Śladowska K, Malinowska-Lipień I, et al. New alternative in the treatment of rheumatoid arthritis: clinical utility of baricitinib. Ther Clin Risk Manag 2019; 15: 275–284.
9. Martinec R, Pinjatela R, Balen D. Quality of life in patients with rheumatoid arthritis – a preliminary study. Acta Clinica Croatica 2019; 58(1): 157.
10. Findeisen KE, Sewell J, Ostor AJK. Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician. Biologics 2021; 15: 343–352, doi: 10.2147/BTT.S252575.
11. Vergne-Salle P, Pouplin S, Trouvin AP, et al. The burden of pain in rheumatoid arthritis: Impact of disease activity and psychological factors. Eur J Pain 2020; 24(10): 1979–1989, doi: 10.1002/ejp.1651.
12. Köhler MB, Günther J, Kaudewitz D, et al. Current Therapeutic Options in the Treatment of Rheumatoid Arthritis. J Clin Med 2019; 8(7): 938.
13. Prasad P, Verma S, Ganguly KN, et al. Rheumatoid arthritis: advances in treatment strategies. Mol Cell Biochem 2023; 478(1): 69–88.
14. Blaess J, Walther J, Petitdemange A. Immunosuppressive agents for rheumatoid arthritis: a systematic review of clinical trials and their current development stage. Ther Adv Musculoskelet Dis 2020; 12: 1759720X20959971, doi: 10.1177/1759720X20959971.
15. Almutair K, Nossent J, Preen D, et al. The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Rheumatol Int 2021; 41(5): 863–877, doi: 10.1007/s00296-020-04731-0.
16. Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol 2005; 23(5 Suppl. 39): S14–S18.
17. Heller GZ, Manuguerra M, Chow R. How to analyze the Visual Analogue Scale: Myths, truths and clinical relevance. Scand J Pain 2016; 13: 67–75, doi: 10.1016/j.sjpain.2016.06.012.
18. Scott D, Ibrahim F, Hill H, et al. The clinical effectiveness of intensive management in moderate established rheumatoid arthritis: The titrate trial. Semin Arthritis Rheum 2020; 50(5): 1182–1190, doi: 10.1016/j.semarthrit.2020.07.014.
19. Choi IA, Kim JH, Hae Chang S, et al. Patient perspectives on biological treatments for inflammatory arthritis: A multi-center study in Korea. Arch Rheumatol 2021; 36(4): 499–509, doi: 10.46497/A.
20. Radu AF, Bungau SG. Nanomedical approaches in the realm of rheumatoid arthritis. Ageing Res Rev 2023; 87: 101927, doi: 10.1016/j.arr.2023.101927.
21. Rubbert-Roth A, Aletaha D, Devenport J, et al. Effect of disease duration and other characteristics on efficacy outcomes in clinical trials of tocilizumab for rheumatoid arthritis. Rheumatology 2021; 60: 682–691.
22. Murray K, Turk M, Alammari Y, et al. Long-term remission and biologic persistence rates: 12-year real-world data. Arthritis Res Ther 2021; 23(1): 25, doi: 10.1186/s13075-020-02380-z.
23. Hamann HDP, Pauling DJ, McHugh N, et al. Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor-treated rheumatoid arthritis patients. Rheumatology (Oxford) 2019; 58(12): 2162–2169, doi: 10.1093/rheumatology/kez188.
24. Cai Y, Zhang J, Liang J, et al. The burden of rheumatoid arthritis: findings from the 2019 global bur-den of diseases study and forecasts for 2030 by Bayesian age-period-cohort analysis. J Clin Med 2023; 12(4): 1291, doi: 10.3390/jcm12041291.
25. Barnabe C, Homik J, Barr GS, et al. The Effect of Different Remission Definitions on Identification of Predictors of Both Point and Sustained Remission in Rheumatoid Arthritis Treated with Anti-TNF Therapy. J Rheumatol 2014; 41(8): 1607–1613, doi: 10.3899/jrheum.131451.
26. Wang K, Liao H, Chen W, et al. Real-world effectiveness and safety of rituximab in the treatment of rheumatoid arthritis: A single-center experience in Taiwan. Int J Rheum Dis 2019; 22(5): 860–868, doi: 10.1111/1756-185X.13511.
27. Khader Y, Beran A, Ghazaleh S, et al. Predictors of remission in rheumatoid arthritis patient treat-ed with biologics: a system review and meta-analysis. Clin Rheumatol 2022; 41(12): 3615–3627, doi: 10.1007/s10067-022-06307-8.
28. Staszkiewicz M, Majorczyk M, Jaworek J. Patients’ opinions on the efficacy of the biological therapy in rheumatic inflammatory diseases. Piel Pol 2017; 1(63): 90–96.
29. Hyrich LK, Deighton C, Watson DK, et al. Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity. Rheumatology (Oxford) 2009; 48(10): 1323–1327, doi: 10.1093/rheumatology/kep242.
30. Neycheva S, Naseva E, Batalov Z, et al. Adherance to biological therapies in patients with rheumatoid arthritis: a retrospective cohort study. Rheumatol Int 2023; 43(7): 1287–1296, doi: 10.1007/s00296-023-05327-0.
Copyright: © 2025 Family Medicine & Primary Care Review. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.